Last reviewed · How we verify
RPESC-RPE-4W
At a glance
| Generic name | RPESC-RPE-4W |
|---|---|
| Sponsor | Luxa Biotechnology, LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPESC-RPE-4W CI brief — competitive landscape report
- RPESC-RPE-4W updates RSS · CI watch RSS
- Luxa Biotechnology, LLC portfolio CI